Product details
Background：Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
• Expression of Interleukin 6 signaling receptors in carotid atherosclerosis., PMID:33350884
• Preclinical development of CD126 CAR-T cells with broad antitumor activity., PMID:33414408
• Physiological effects of modulating the interleukin-6 axis., PMID:29982781
• Increased IL-6 and Potential IL-6 trans-signalling in the airways after an allergen challenge., PMID:33471392
• IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization., PMID:39229261
• Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism., PMID:34576053
• Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19., PMID:35634332
• M1-Like Macrophages Modulate Fibrosis and Inflammation of Orbital Fibroblasts in Graves’ Orbitopathy: Potential Relevance to Soluble Interleukin-6 Receptor., PMID:36617890
• The IL-6-neutralizing sIL-6R-sgp130 buffer system is disturbed in patients with type 2 diabetes., PMID:31237452
• Soluble interleukin-6 receptor-mediated innate immune response to DNA and RNA viruses., PMID:23946454
